Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo.

Li X, Liu S, Huang H, Liu N, Zhao C, Liao S, Yang C, Liu Y, Zhao C, Li S, Lu X, Liu C, Guan L, Zhao K, Shi X, Song W, Zhou P, Dong X, Guo H, Wen G, Zhang C, Jiang L, Ma N, Li B, Wang S, Tan H, Wang X, Dou QP, Liu J.

Cell Rep. 2013 Jan 31;3(1):211-22. doi: 10.1016/j.celrep.2012.11.023. Epub 2012 Dec 21.

2.

Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation.

Liu N, Huang H, Liu S, Li X, Yang C, Dou QP, Liu J.

Toxicol In Vitro. 2014 Apr;28(3):419-25. doi: 10.1016/j.tiv.2013.12.008. Epub 2013 Dec 27.

PMID:
24373880
3.

The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.

Liu N, Huang H, Xu L, Hua X, Li X, Liu S, Yang C, Zhao C, Zhao C, Li S, Dou QP, Liu J.

Toxicol Lett. 2014 Jan 30;224(3):333-40. doi: 10.1016/j.toxlet.2013.11.021. Epub 2013 Nov 26.

PMID:
24291039
4.

Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system.

Felth J, Lesiak-Mieczkowska K, D'Arcy P, Haglund C, Gullbo J, Larsson R, Linder S, Bohlin L, Fryknäs M, Rickardson L.

Invest New Drugs. 2013 Jun;31(3):587-98. doi: 10.1007/s10637-012-9902-y. Epub 2012 Nov 20.

PMID:
23179339
5.

Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.

Shi X, Lan X, Chen X, Zhao C, Li X, Liu S, Huang H, Liu N, Zang D, Liao Y, Zhang P, Wang X, Liu J.

Sci Rep. 2015 Apr 8;5:9694. doi: 10.1038/srep09694.

6.

Gambogic acid enhances proteasome inhibitor-induced anticancer activity.

Huang H, Chen D, Li S, Li X, Liu N, Lu X, Liu S, Zhao K, Zhao C, Guo H, Yang C, Zhou P, Dong X, Zhang C, Guanmei, Dou QP, Liu J.

Cancer Lett. 2011 Feb 28;301(2):221-8. doi: 10.1016/j.canlet.2010.12.015. Epub 2011 Jan 7.

7.

Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors.

Cheemanapalli S, Anuradha CM, Madhusudhana P, Mahesh M, Raghavendra PB, Kumar CS.

Anticancer Agents Med Chem. 2016;16(11):1496-1510.

PMID:
27173965
8.

Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.

Troiano V, Scarbaci K, Ettari R, Micale N, Cerchia C, Pinto A, Schirmeister T, Novellino E, Grasso S, Lavecchia A, Zappalà M.

Eur J Med Chem. 2014 Aug 18;83:1-14. doi: 10.1016/j.ejmech.2014.06.017. Epub 2014 Jun 10.

PMID:
24946214
9.

Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.

Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.

J Nucl Med. 2012 Nov;53(11):1764-71. doi: 10.2967/jnumed.111.101295. Epub 2012 Oct 10.

10.

Hinokitiol copper complex inhibits proteasomal deubiquitination and induces paraptosis-like cell death in human cancer cells.

Chen X, Zhang X, Chen J, Yang Q, Yang L, Xu D, Zhang P, Wang X, Liu J.

Eur J Pharmacol. 2017 Nov 15;815:147-155. doi: 10.1016/j.ejphar.2017.09.003. Epub 2017 Sep 5.

PMID:
28887042
11.

Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.

Liu N, Li X, Huang H, Zhao C, Liao S, Yang C, Liu S, Song W, Lu X, Lan X, Chen X, Yi S, Xu L, Jiang L, Zhao C, Dong X, Zhou P, Li S, Wang S, Shi X, Dou PQ, Wang X, Liu J.

Oncotarget. 2014 Jul 30;5(14):5453-71.

12.

Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.

Liu Y, Qian K, Wang CY, Chen CH, Yang X, Lee KH.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7530-3. doi: 10.1016/j.bmcl.2012.10.041. Epub 2012 Oct 16.

PMID:
23122524
13.

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA, Keats JJ, Braggio E, Sereduk C, Mousses S, Stewart AK.

Blood. 2011 Apr 7;117(14):3847-57. doi: 10.1182/blood-2010-08-304022. Epub 2011 Feb 2.

14.

Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP.

Wang J, Zhao Q, Qi Q, Gu HY, Rong JJ, Mu R, Zou MJ, Tao L, You QD, Guo QL.

J Cell Biochem. 2011 Feb;112(2):509-19. doi: 10.1002/jcb.22941.

PMID:
21268072
15.

Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells.

Nehybová T, Šmarda J, Daniel L, Stiborek M, Kanický V, Spasojevič I, Preisler J, Damborský J, Beneš P.

Int J Mol Sci. 2017 Mar 29;18(4). pii: E729. doi: 10.3390/ijms18040729.

16.

Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.

Hui KF, Chiang AK.

Int J Cancer. 2014 Dec 15;135(12):2950-61. doi: 10.1002/ijc.28924. Epub 2014 May 5.

17.

MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.

Zhang X, Schulz R, Edmunds S, Krüger E, Markert E, Gaedcke J, Cormet-Boyaka E, Ghadimi M, Beissbarth T, Levine AJ, Moll UM, Dobbelstein M.

Mol Cell. 2015 Jul 16;59(2):243-57. doi: 10.1016/j.molcel.2015.05.036. Epub 2015 Jul 2.

18.

New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity.

Neilsen PM, Pehere AD, Pishas KI, Callen DF, Abell AD.

ACS Chem Biol. 2013 Feb 15;8(2):353-9. doi: 10.1021/cb300549d. Epub 2012 Nov 28.

PMID:
23190346
19.

Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia cells.

Li R, Chen Y, Zeng LL, Shu WX, Zhao F, Wen L, Liu Y.

Toxicology. 2009 Aug 3;262(2):98-105. doi: 10.1016/j.tox.2009.04.059. Epub 2009 May 9.

PMID:
19433130
20.

Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells.

Chang HY, Huang TC, Chen NN, Huang HC, Juan HF.

Cell Death Dis. 2014 Nov 27;5:e1540. doi: 10.1038/cddis.2014.504.

Supplemental Content

Support Center